• Diabetes

Humalog Generic Name & Formulations

General Description

Insulin lispro (rDNA origin) 100 Units/mL, 200 Units/mL; soln for SC inj or continuous subcutaneous insulin infusion pump; contains zinc, m-cresol.

How Supplied

Humalog Mix75/25, Humalog Mix50/50, Humalog vials (10mL)—1; Humalog Mix, Humalog U-100 KwikPen (prefilled) (3mL), Humalog U-100 Tempo Pen (prefilled) (3mL), Humalog U-100 Junior KwikPen (prefilled) (3mL), Humalog U-200 KwikPen (prefilled) (3mL)—5; Humalog cartridges (3mL)—5; HumaPen LUXURA HD (inj device, uses Humalog cartridges)—1


Mechanism of Action

Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Humalog Indications



Humalog Dosage and Administration

Adults and Children

<3yrs: not recommended. Onset ≤15mins, peak approx. 0.5–1.5hrs, duration approx. 3–5hrs. ≥3yrs: Give SC, either by injection or continuous infusion external pump. SC inj: give 15 mins before meal or immediately after a meal; use with an intermediate or long-acting insulin. Rotate inj sites. Continuous SC infusion pump: do not use diluted or mixed insulins in external pumps; change the Humalog in the reservoir at least every 7 days, change the infusion sets and insertion site at least every 3 days.

Humalog Contraindications


During episodes of hypoglycemia.

Humalog Boxed Warnings

Not Applicable

Humalog Warnings/Precautions


Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, cartridges, or syringes between patients, even if the needle is changed. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyperglycemia of hypoglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen, administration site, and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Pregnancy. Nursing mothers.

Humalog Pharmacokinetics


Peak serum levels: 30–90 minutes after dosing. Absolute bioavailability: 55–77%. Mean time to maximum concentration: 1 hour after administration.


Mean volume of distribution: 1.55 L/kg (for 0.1 U/kg dose); 0.72 L/kg (for 0.2 U/kg dose).




Half-life: 51–55 minutes. Mean clearance: 21.0 mL/min/kg (for 0.1 U/kg); 9.6 mL/min/kg (for 0.2 U/kg).

Humalog Interactions


Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. When mixing insulin lispro with other insulins, draw insulin lispro into syringe first and inject mixture immediately.

Humalog Adverse Reactions

Adverse Reactions

Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.

Humalog Clinical Trials

See Literature

Humalog Note

Not Applicable

Humalog Patient Counseling

See Literature